Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ubrogepant (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms ACHIEVE II
  • Sponsors Allergan

Most Recent Events

  • 26 Apr 2022 Results of pooled analysis from ACHIEVE I and ACHIEVE II trials demonstrating therapeutic benefit at 1-Hour post-dose presented at the 74th Annual Meeting of the American Academy of Neurology 2022
  • 07 Dec 2021 Results of post hoc pooled analysis, assessing efficacy endpoints from ACHIEVE I and ACHIEVE II (n=2247) and safety outcomes from NCT02873221 (n=813); published in the Advances in Therapy
  • 18 Aug 2021 Results of an analysis from four clinical trials: SAMURAI, ACHEIVE III, SPARTAN and NCT02873221 assessing use of placebo followed by placebo in randomized trials and its ethical standpoint published in the Cephalalgia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top